ArticleBMC gastroenterology2025
Visit‑to‑visit variability of inflammation-immunity indices and prognosis in hepatocellular carcinoma.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundInflammatory–immune blood indices such as the systemic immune‑inflammation index (SII) relate to outcomes in hepatocellular carcinoma (HCC). Visit‑to‑visit variability (VVV) may capture instability of host inflammatory homeostasis that is not reflected by average levels. We examined whether early VVV of these indices predicts overall survival (OS) and adds discriminatory value beyond standard prognostic factors and mean levels.
methodsWe conducted a single‑center retrospective cohort of adults with HCC from June 2020 to December 2024. All laboratory “visits” within days 0–90 informed per‑patient VVV; the primary exposure was SII variability independent of the mean (SII‑VIM), with average real variability (ARV) and SD/CV% as secondary metrics. The primary outcome was OS from the day‑90 landmark. Predictive increment was assessed by change in Harrell’s C‑index, time‑dependent AUC (1 and 2 years), and NRI/IDI with bootstrap internal validation; sensitivity analyses included a 0–180‑day window, time‑varying rolling VVV, and multiple imputation (m = 20).
resultsOf 780 patients, 528 survived to the landmark and were analyzed. Median follow-up was 25.1 months with 216 deaths (41%). Each 1-SD increase in SII-VIM was associated with higher mortality (adjusted HR 1.26, 95% CI 1.12–1.41); the highest versus lowest quartile yielded HR 1.72 (95% CI 1.25–2.36). Splines showed a monotonic dose–response. Adding SII-VIM improved discrimination from C-index 0.68 to 0.71 and increased AUC from 0.70 to 0.73 at 1 year and from 0.67 to 0.70 at 2 years; continuous NRI was 0.14 (95% CI 0.06–0.22) and IDI 0.018 (95% CI 0.008–0.030). Results were consistent using ARV (HR 1.20), a 0–180-day window (HR 1.22), and time-varying analyses (HR 1.18).
conclusionsEarly visit-to-visit variability—particularly SII-VIM—was independently associated with worse OS in HCC and added modest, clinically meaningful discrimination beyond standard factors and mean levels, and prospective validation is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.